Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients

被引:103
作者
Inaba, M.
Okuno, S.
Imanishi, Y.
Yamada, S.
Shioi, A.
Yamakawa, T.
Ishimura, E.
Nishizawa, Y.
机构
[1] Osaka City Univ, Grad Sch Med, Dept Endocrinol Metab & Mol Med, Abeno Ku, Osaka 5458585, Japan
[2] Osaka City Univ, Grad Sch Med, Dept Nephrol, Abeno Ku, Osaka 5458585, Japan
[3] Shirasagi Hosp Kidney Ctr, Osaka, Japan
关键词
FGF-23; hemodialysis; phosphate; type; 2; diabetes; vascular calcification;
D O I
10.1007/s00198-006-0154-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Fibroblast growth factor (FGF) 23 is a recently identified circulating factor that regulates phosphate (Pi) metabolism. Since the derangement of Pi control is an important risk factor for vascular calcification, we investigated the importance of plasma FGF-23 in the development of vascular calcification in the aorta and peripheral artery in hemodialysis patients with and without diabetes mellitus (DM). Methods: Male hemodialysis patients with DM (n=32) and without DM (n=56) were examined. Plasma samples were obtained before the start of dialysis sessions, and the FGF-23 levels were determined by enzyme-linked immunosorbent assay. Roentgenography of the aorta and hand artery was performed, and visible vascular calcification was evaluated by one examiner, who was blinded to the patient characteristics. Results: In the 56 non-DM hemodialysis patients, vascular calcification was found in the hand artery in 5 patients (8.9%) and in the aorta in 23 patients (41.1%). These levels were significantly lower (p < 0.05) than in the 32 DM patients, of whom, 19 (59.4%) and 21 (65.6%) had vascular calcification of the hand artery and aorta, respectively. Multiple regression analyses performed separately in the non-DM and DM patients showed that the plasma FGF-23 level, CaxPi product, and body weight are independent factors significantly associated with hand-artery calcification and that diastolic blood pressure is associated with aorta calcification in non-DM patients. In DM patients, the plasma FGF-23 level and hemodialysis duration emerged as independent factors associated with hand-artery calcification and diastolic blood pressure was associated with aorta calcification. The independent association of the plasma FGF-23 level with hand-artery calcification was retained in both non-DM and DM patients when adjusted for the CaxPi product. Conclusions: Our findings show that the plasma FGF-23 level is an independent factor negatively associated with peripheral vascular calcification in the hand artery, but not in the aorta, in both male non-DM and DM hemodialysis patients, even when adjusted for the CaxPi product. This study raises the possibility that the plasma FGF-23 level may provide a reliable marker for Moenckeberg's medial calcification in male hemodialysis patients, independent of its regulatory effect on Pi metabolism.
引用
收藏
页码:1506 / 1513
页数:8
相关论文
共 31 条
[1]  
American Diabetes Association, 2005, DIABETES CARE S1, V21, pS5
[2]   End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? [J].
Arici, M ;
Walls, J .
KIDNEY INTERNATIONAL, 2001, 59 (02) :407-414
[3]   An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia [J].
Benet-Pagès, A ;
Orlik, P ;
Strom, TM ;
Lorenz-Depiereux, B .
HUMAN MOLECULAR GENETICS, 2005, 14 (03) :385-390
[4]  
Cozzolino M, 2001, J AM SOC NEPHROL, V12, P2511, DOI 10.1681/ASN.V12112511
[5]   Pathophysiological mechanisms of vascular calcification in end-stage renal disease [J].
Davies, MR ;
Hruska, KA .
KIDNEY INTERNATIONAL, 2001, 60 (02) :472-479
[6]   Autosomal dominant hypophosphatemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate-wasting disorder [J].
Econs, MJ ;
McEnery, PT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :674-681
[7]  
Edmonds ME, 2000, Z KARDIOL, V89, P101
[8]  
GOMEZ B, 1995, CLIN CHEM, V41, P1560
[9]   FGF-23 is elevated by chronic hyperphosphatemia [J].
Gupta, A ;
Winer, K ;
Econs, MJ ;
Marx, SJ ;
Collins, MT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (09) :4489-4492
[10]   FGF-23 in patients with end-stage renal disease on hemodialysis [J].
Imanishi, Y ;
Inaba, M ;
Nakatsuka, K ;
Nagasue, K ;
Okuno, S ;
Yoshihara, A ;
Miura, M ;
Miyauchi, A ;
Kobayashi, K ;
Miki, T ;
Shoji, T ;
Ishimura, E ;
Nishizawa, Y .
KIDNEY INTERNATIONAL, 2004, 65 (05) :1943-1946